News & Events

Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic

Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board. Adriano Chiò is a neurologist

Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed

Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior consultant neurology and Head of ALS at Karolinska University Hospital and Karolinska Institute as the second member of its newly-formed Scientific Advisory Board. Dr. Ingre runs the ALS clinic at

Viken – September 19, 2023 – Today, Swedish biopharmaceutical company TikoMed AB announced the formation of its Scientific Advisory Board (SAB). The SAB will work cohesively with management to advance the company’s clinical development of ILB, TikoMeds drug in Phase 2 development in ALS. The board will integrate highly experienced